Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.505 1.01% 0.02
ACRX closed down 4.49 percent on Wednesday, February 19, 2020, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ACRX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 1.01%
Expansion Breakdown Bearish Swing Setup 1.01%
New 52 Week Low Weakness 1.01%
Below Lower BB Weakness 1.01%
Down 3 Days in a Row Weakness 1.01%
Down 4 Days in a Row Weakness 1.01%
Down 5 Days in a Row Weakness 1.01%
Lower Bollinger Band Touch Weakness 1.01%
Oversold Stochastic Weakness 1.01%
MACD Bearish Signal Line Cross Bearish -3.53%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Chemistry Cancer Pain Chemical Compounds Treatment Of Cancer Organic Compounds Clinical Trial Ethers Injury Piperidines Fentanyl Stage Specialty Pharmaceutical Breakthrough Pain Sufentanil Thiophenes

Is ACRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.09
52 Week Low 1.49
Average Volume 832,838
200-Day Moving Average 2.26
50-Day Moving Average 1.93
20-Day Moving Average 1.69
10-Day Moving Average 1.65
Average True Range 0.08
ADX 26.52
+DI 12.63
-DI 33.08
Chandelier Exit (Long, 3 ATRs ) 1.77
Chandelier Exit (Short, 3 ATRs ) 1.72
Upper Bollinger Band 1.82
Lower Bollinger Band 1.55
Percent B (%b) -0.23
BandWidth 15.88
MACD Line -0.09
MACD Signal Line -0.08
MACD Histogram -0.0082
Fundamentals Value
Market Cap 67.61 Million
Num Shares 45.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -1.35
Price-to-Sales 5.25
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.66
Resistance 3 (R3) 1.67 1.64 1.63
Resistance 2 (R2) 1.64 1.59 1.63 1.62
Resistance 1 (R1) 1.56 1.57 1.55 1.55 1.61
Pivot Point 1.53 1.53 1.52 1.52 1.53
Support 1 (S1) 1.45 1.48 1.44 1.44 1.37
Support 2 (S2) 1.42 1.46 1.41 1.36
Support 3 (S3) 1.34 1.42 1.35
Support 4 (S4) 1.33